ライフサイエンスコーパス: Bacille Calmette-Guerin

1 m smegmatis , Mycobacterium tuberculosis and bacille Calmette-Guerin.

2 ce and C57BL/6 mice previously infected with bacille Calmette-Guerin.

3 ination of 10 of these 19 patients with live bacille Calmette-Guerin.

4 in or for those who cannot be immunized with bacille Calmette-Guerin.

5 h superficial bladder cancer who have failed bacille Calmette-Guerin.

6 autologous, DNP-modified vaccine mixed with bacille Calmette-Guerin.

7 acteria such as M. tuberculosis and M. bovis Bacille-Calmette-Guerin.

8 od to restrict growth of Mycobacterium bovis bacille Calmette Guerin and Mycobacterium tuberculosis w

9 n vitro activity against Mycobacterium bovis bacille Calmette-Guerin and virulent M. tuberculosis.

10 In sharp contrast, the vaccine strain bacille Calmette-Guerin as well as RD-1 and ESAT-6 mutan

11 s to study the uptake of Mycobacterium bovis bacille Calmette Guerin (BCG) into murine macrophages.

12 The variable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberc

13 from tuberculosis every year even though the bacille Calmette Guerin (BCG) vaccine has been available

14 ed as an intravesical agent in patients with bacille Calmette-Guerin (BCG) -refractory transitional c

15 led whole-promastigote vaccine cocktail plus bacille Calmette-Guerin (BCG) adjuvant significantly red

16 rget (ESAT)-6, that are absent from M. bovis bacille Calmette-Guerin (BCG) and most environmental myc

17 ow-growing mycobacteria, Mycobacterium bovis bacille Calmette-Guerin (BCG) and Mycobacterium avium, b

18 A human mycobacterial challenge model, using bacille Calmette-Guerin (BCG) as a surrogate for a Mycob

19 Use of bacille Calmette-Guerin (BCG) as a surrogate for human M

20 Live attenuated Bacille Calmette-Guerin (BCG) bacillus is the only licen

21 uated strain of Mycobacterium bovis known as bacille Calmette-Guerin (BCG) has been widely used as a

22 Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in p

23 Bacille Calmette-Guerin (BCG) immunity can be studied as

24 tify immune correlates of TB disease risk in Bacille Calmette-Guerin (BCG) immunized infants from the

25 CD8 T cells specific to Mycobacterium bovis bacille Calmette-Guerin (BCG) in the lungs, and the IFN-

26 When PMCs were stimulated with bacille Calmette-Guerin (BCG) in vitro, they expressed I

27 Mycobacterium avium and Mycobacterium bovis Bacille Calmette-Guerin (BCG) in vitro.

28 obacterium smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG) in which a very high propo

29 d major expansion during Mycobacterium bovis Bacille Calmette-Guerin (BCG) infection and a clear memo

30 th T cells responding to Mycobacterium bovis bacille Calmette-Guerin (BCG) infection and disrupt gran

31 al iron-enriched diet on Mycobacterium bovis bacille Calmette-Guerin (BCG) infection.

32 The tuberculosis (TB) vaccine bacille Calmette-Guerin (BCG) is a live attenuated organ

33 Bacille Calmette-Guerin (BCG) is a live, attenuated stra

34 Bacille Calmette-Guerin (BCG) is an attenuated strain of

35 urrently available vaccine for tuberculosis, bacille Calmette-Guerin (BCG) is the most widely used va

36 o, pleural mesothelial cells stimulated with bacille Calmette-Guerin (BCG) or interferon (IFN)-gamma

37 with IGRAs in individuals with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy

38 sate to detect antibody responses induced by bacille Calmette-Guerin (BCG) vaccination and active tub

39 sessed using intradermal Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate

40 ction with environmental mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the

41 Bacille Calmette-Guerin (BCG) vaccination has been sugge

42 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy vol

43 Bacille Calmette-Guerin (BCG) vaccination induces a mark

44 Bacille Calmette-Guerin (BCG) vaccination may induce per

45 bacterial Ags in the context of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T

46 Bacille Calmette-Guerin (BCG) vaccination, known to indu

47 mized to receive percutaneous or intradermal bacille Calmette-Guerin (BCG) vaccination.

48 Approximately 100 million doses of bacille Calmette-Guerin (BCG) vaccine are given each yea

49 tection conferred by the Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine are multifaceted a

50 Because Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccine can confer protect

51 Policies regarding the use of the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis v

52 The existence of therapeutic agents and the bacille Calmette-Guerin (BCG) vaccine have not significa

53 er (250 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tub

54 During 1986-1989, a bacille Calmette-Guerin (BCG) vaccine trial was carried

55 whole-cell melanoma vaccine, Canvaxin, plus Bacille Calmette-Guerin (BCG) versus placebo plus BCG.

56 )mac-infected macaques previously exposed to bacille Calmette-Guerin (BCG) were reinfected with BCG,

57 radiated autologous tumor cells admixed with bacille Calmette-Guerin (BCG) were used to vaccinate pat

58 We have previously established that bacille Calmette-Guerin (BCG), an attenuated form of Myc

59 Bacille Calmette-Guerin (BCG), an attenuated strain of M

60 The cells were infected with bacille Calmette-Guerin (BCG), and intracellular mycobac

61 transposed apparently randomly in M. phlei, Bacille Calmette-Guerin (BCG), and M. tuberculosis.

62 is expressed in M. tuberculosis and M. bovis Bacille Calmette-Guerin (BCG), using reverse transcripti

63 obacterium smegmatis and Mycobacterium bovis bacille Calmette-Guerin (BCG), which respectively induce

64 rus of macaques (SIVmac)/Mycobacterium bovis bacille Calmette-Guerin (BCG)-coinfected macaque model.

65 an immunodeficiency virus (HIV)-infected and bacille Calmette-Guerin (BCG)-immunized adults with CD4

66 tuberculosis Ag 85A (M.85A), strongly boosts bacille Calmette-Guerin (BCG)-induced Ag 85A specific CD

67 ial protection in Mycobacterium bovis strain bacille Calmette-Guerin (BCG)-induced granulomas using a

68 In Mycobacterium bovis Bacille Calmette-Guerin (BCG)-infected wild-type mice, t

69 N-gamma-secreting T cells when used alone in bacille Calmette-Guerin (BCG)-naive healthy volunteers.

70 cterium bovis bloodstream infection (BSI) in bacille Calmette-Guerin (BCG)-vaccinated children with h

71 t two treatments, PMCV was administered with bacille Calmette-Guerin (BCG).

72 teria such as Mycobacterium tuberculosis and bacille Calmette-Guerin (BCG).

73 e Mycobacterium bovis-derived vaccine strain bacille Calmette-Guerin (BCG).

74 h an attenuated form of Mycobacterium bovis, bacille Calmette-Guerin (BCG).

75 ing the live attenuated tuberculosis vaccine bacille Calmette-Guerin (BCG).

76 cerebrally infected with Mycobacterium bovis bacille Calmette-Guerin (BCG).

77 rculosis but not the vaccine strain M. bovis bacille Calmette-Guerin (BCG).

78 reaction directed against the mycobacterium bacille Calmette-Guerin (BCG).

79 ts were vaccinated with one of four doses of bacille Calmette-Guerin (BCG): The doses contained very

80 45 countries was 2.3 weeks (IQR 1.4-4.6) for bacille Calmette-Guerin (BCG); 2.4 weeks (1.2-3.3) for d

81 igs that had or had not been vaccinated with Bacille-Calmette Guerin (BCG).

82 pulmonary infection with Mycobacterium bovis Bacille-Calmette-Guerin (BCG).

83 ection and inhibited NO-dependent killing of bacille Calmette-Guerin by macrophages.

84 We show in this article that although bacille Calmette-Guerin controlled M. tuberculosis growt

85 esus monkeys were immunized with recombinant bacille Calmette-Guerin expressing the full-length measl

86 toplasmically into macrophages infected with bacille Calmette-Guerin expressing the green fluorescent

87 n to be an effective combination therapy for bacille Calmette-Guerin failures.

88 apy is proposed as a second-line therapy for bacille Calmette-Guerin failures.

89 The addition of interferon to bacille Calmette-Guerin has proven to be an effective co

90 infected with Mycobacterium tuberculosis or bacille Calmette-Guerin have been shown to facilitate pr

91 Intravesical bacille Calmette-Guerin (including a maintenance regimen

92 Bacille Calmette-Guerin is the most effective therapy fo

93 Mycobacterium tuberculosis vaccines to boost bacille Calmette-Guerin or for those who cannot be immun

94 nstrate that exposure of Mycobacterium bovis Bacille Calmette-Guerin or Mycobacterium marinum to thia

95 cells within hepatic granulomas triggered by Bacille Calmette-Guerin or Mycobacterium tuberculosis.

96 induced by infection with M. tuberculosis or bacille Calmette-Guerin, or treatment with LPS or TNF-al

97 vaccination involves the use of recombinant bacille Calmette-Guerin (rBCG) overexpressing protective

98 troduced and existing ones improved to treat bacille Calmette-Guerin-refractory superficial bladder c

99 cterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin, release MVs when growing in bot

100 Infection with Mycobacterium bovis bacille Calmette-Guerin resulted in approximately 10-fol

101 tients who receive intravesical therapy with bacille Calmette-Guerin should be considered for ongoing

102 cterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin similarly home to established gr

103 acterial antigens shown previously to induce bacille Calmette-Guerin-specific gammadelta T cells.

104 chronic medical illness, isoniazid use, and bacille Calmette-Guerin strain did not substantially aff

105 Bacille Calmette Guerin-vaccinated children were more li

106 candidate, M72/AS01, in a phase IIa trial of bacille Calmette-Guerin-vaccinated, HIV-uninfected, and

107 eactivity to nontuberculous mycobacteria and bacille Calmette-Guerin vaccination may account for a pr

108 Bacille Calmette-Guerin vaccination, tuberculosis preval

109 tory of a positive PPD skin test result or a bacille Calmette-Guerin vaccination.

110 is challenge compared with standard M. bovis bacille Calmette-Guerin vaccination.

111 fers poor specificity in those receiving the bacille Calmette-Guerin vaccine and poor sensitivity in

112 Research into the bacille Calmette-Guerin vaccine demonstrated the importa

113 d, controlled trials of the effectiveness of bacille Calmette-Guerin vaccine in preventing active tub

114 The bacille Calmette-Guerin vaccine provides very efficient

115 The failure of the bacille Calmette-Guerin vaccine, synergy between AIDS an

116 the variable efficacy of the currently used bacille Calmette-Guerin vaccine.

117 inguish exposure to M. tuberculosis from the Bacille-Calmette-Guerin vaccine strain, they currently l

118 Failure to replace Bacille Calmette-Guerin vaccines with efficacious anti-t